contact@carpem.fr

Valorisation

Valorisation

 

Development of core facilities allowing to enter in clinics, the advances of translational research

Each research groups participating to this task force is strongly implicated in hospital laboratories and they make all effort to benefit rapidly the patients of new biomarker identifications (see platform of molecular oncology)

 

Valorisation

Christine Perret’s team is partner of the CReMEC Consortium supported by the Medicen Paris Biocluster, focused on therapeutic innovation (http://www.medicen.org/): this consortium, which includes 3 Pharmaceutical companies (Servier, Ipsen and Sanofi-Aventis), one biotech company (OncoDesign) and academics, aims at creating new standardized rodent models of human primary tumors or transgenic mice.

Pierre Laurent-Puig developed collaboration with Myriad-Genetics and InteGragen, Biomerieux, and filed patents PCT/EP2009/057394; PCT/FR2009/050918. 

Jessica Zucman-Rossi’s team collaborates with IntegraGen to translate genomic discoveries in clinical practice.

Elizabeth Macintyre’s team works within two networks for European standardization and optimization of lymphoid cancer diagnostics: EuroClonality in collaboration with Invivoscribe (IVS) for molecular clonality diagnostic and EuroFlow with Becton Dickinson Biosciences (BDB) for multiparameter cytometric profiling, with the royalities from collectively patented and licensed products from 5th and 6th PCRDT programs being used for European dissemination and harmonisation.

 

Expected impacts listed in the work program

The project aims to produce breakthrough knowledge on four critical aspects of cancer care: prognostic prediction, identification of drivers for intervention, identification of new markers for pharmacogenetic prediction, tools validated for targeted and personalized medicine. In the medium term we foresee impacts on improved patient survival as a consequence of better outcome prediction and the discovery of oncogenic addiction loops amenable for selective target. Therefore, impacts of the program will contribute to ultimately reducing patient mortality and also integrate international basic-clinical scientific excellence. The inclusion of hematological cancers within a predominantly solid tumor program, with lymphomas providing the intermediary with leukemias, will encourage bidirectional synergy of this research program.